Alizyme saw its share price rise by as much as 9% during trading on the London Stock Exchange yesterday after the UK biotechnology company said that the it had agreed the terms of a pivotal Phase III clinical trial of its irritable bowel syndrome drug, renzapride, with the US Food and Drug Administration.
The trial will assess whether doses of renzapride, taken either as 4mg once daily or 2mg twice daily, provide improved relief for patients with constipation-predominant irritable bowel syndrome versus placebo. Alizyme aims to recruit up to 1,700 women between the ages of 18 and 65 who will be treated over a 12-week period, with recruitment set to begin during the fourth quarter of the year. Final results are expected to be available in the first half of 2007.
Richard Palmer, the firm’s chief executive, commented: “This is a major achievement for both renzapride and the company as it takes a second product from our portfolio into Phase III clinical development.”